Thyroid Eye Disease

Teprotumumab may lower IOP in patients with thyroid eye disease

Treatment with teprotumumab is associated with a reduction in intraocular pressure (IOP) in patients with thyroid eye disease (TED), according to a study. In this retrospective review, the IOP, extent of proptosis, and clinical activity score of 17 patients (34 eyes) with TED who were treated with teprotumumab were analyzed...